A188 REAL-LIFE MANAGEMENT OF CHRONIC HEPATITIS C VIRUS INFECTION IN CANADA: DESCRIPTION OF PATIENT PROFILE, PROGNOSTIC FACTORS AND TREATMENT STRATEGIES

Most recent major treatment guidelines recommend considering the patient profile and baseline prognostic factors (genotype, fibrosis level, treatment history) in the management of chronic hepatitis C virus (HCV) infections (CHC). There is, therefore, a need to better characterize clinician decision-making in real-life CHC management in Canada. To describe the patient profile, prognostic factors and treatment strategies used in Canadian real-life CHC management. Multicenter chart review of CHC patients diagnosed from 2005 to 2012. Patient data were extracted for a minimum of 2 years after CHC diagnosis. 250 patients were included with a mean (SD) follow-up after diagnosis of 5.9 (2.3) years. Table1 summarizes the patient/disease characteristics at CHC diagnosis and the mode of management. A majority of patients (70.4%) received some antiviral treatment, with a lower proportion of treated G1 patients vs. non-G1 patients (64% vs. 76.7%). The most common initial treatments were IFN/RBV dual therapy (68.4%) and NS3/4-containing IFN/RBV therapy (19.3%); Among non-G1 patients, 92.4% were treated with IFN/RBV dual therapy. SVR was achieved by 51.5% of patients (G1: 44.7%; non-G1: 62.2%), 19.3% relapsed and 11.1% were non-responders with initial treatment. The majority of treated patients (72.2%) experienced AEs, the most common ones being fatigue (33%), anemia (27.3%), insomnia (21.6%), neutropenia (18.8%). Two deaths were reported. Despite the majority of HCV patients having mild fibrosis and being treated, most frequently with dual IFN/RBV therapy, SVR rates were low prior to the all-oral DAA era, highlighting the need for more efficacious treatments and suggesting that recommendations to still use IFN are not justifiable. Patient/Disease Characteristics at HCV Diagnosis *Most common ‡% of treated patients Abbvie corporation